RNAi developers see surge in IPOs and funding as industry interest revives

BioPharma Dive’s latest data‑visualization series highlights a rapid rise in interest and investment for companies developing RNA interference (RNAi) medicines.

After a years‑long lull, more than two dozen biotech firms have gone public in 2026, many focused on RNAi therapies that have shown clinical promise or are expected to outperform existing treatments.

Notable IPOs include ADARx Pharmaceuticals and City Therapeutics, with ADARx becoming the first RNAi developer to list on Nasdaq since 2014 and raising one of the largest offerings this year.